Pacira Pharmaceuticals Inc., of Parsippany, N.J., reported fourth-quarter GAAP net income of $8.3 million, or 20 cents per diluted share, and full-year 2018 GAAP net loss of $500,000, or 1 cent per basic and diluted share, on fourth-quarter Exparel (bupivacaine extended release) net sales of $94.4 million – a 20 percent increase over $78.7 million in the same period in 2017 – and full-year 2018 net sales of $331.1 million, a 17 percent increase over $282.9 million reported in 2017.